(R)-6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-amine | 828926-09-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (R)-6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-amine
• 英文别名: 6-piperidin-1-ylmethyl-1,2,3,4-tetrahydro-naphthalene-1(R)-ylamine；(R)-6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-ylamine；6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-amine；(1R)-6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-amine
• CAS: 828926-09-6
• 化学式: C₁₆H₂₄N₂
• 分子量: 244.38
• InChiKey: YXEFAQFQGVGUQT-MRXNPFEDSA-N

物化性质

• 沸点：
  370.9±30.0 °C(Predicted)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-amine 、 5-苯(甲)酰戊酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-oxo-6-phenyl-N-[(1R)-6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-yl]hexanamide
  参考文献：
  名称：

  Discovery of Potent, Orally Bioavailable Phthalazinone Bradykinin B1 Receptor Antagonists

  摘要：

  The bradykinin B1 receptor is rapidly induced upon tissue injury and inflammation, stimulating the production of inflammatory mediators resulting in plasma extravasation, leukocyte trafficking, edema, and pain. We have previously reported on sulfonamide and sulfone-based B1 antagonists containing a privileged bicyclic amine moiety leading to potent series of 2-oxopiperazines. The suboptimal pharmacokinetics and physicochemical properties of the oxopiperazine sulfonamides led us to seek B1 antagonists with improved druglike properties. Using a pharmacophore model containing a bicyclic amine as anchor, we designed a series of amide antagonists with targeted physicochemical properties. This approach led to a novel series of potent phthalazinone B1 antagonists, where we successfully replaced a sulfonamide acceptor with a cyclic carbonyl unit. SAR studies revealed compounds with subnanomolar B1 binding affinity. These compounds demonstrate excellent cross-species PK properties with high oral bioavailability and potent activity in a rabbit biochemical challenge pharmacodynamic study.

  DOI：

  10.1021/jm200808v
• 作为产物：
  描述：

  4-[(4-甲基苯基)磺酰基]哌啶盐酸盐 在 溶剂黄146 盐酸 、 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 dimethyl sulfide borane 、 叠氮磷酸二苯酯 、 sodium cyanoborohydride 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氟乙酸 、 (R)-2-甲基-CBS-恶唑硼烷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 48.0h， 生成 (R)-6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-amine
  参考文献：
  名称：

  [EN] SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS
  [FR] TÉTRAHYDROAZOLOPYRAZINES SULFONYLÉES ET LEUR UTILISATION EN TANT QUE PRODUITS MÉDICAMENTEUX

  摘要：

  本发明涉及磺酰化四氢咯啉吡嗪，其制备方法，含有这些化合物的药物产品以及用于制备药物产品的取代吲哚化合物的使用（式I）。

  公开号：

  WO2010099938A1

文献信息

• Piperazine derivatives and methods of use
  申请人：Chen J. Jian

  公开号：US20050014749A1

  公开（公告）日：2005-01-20

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和炎症介导的疾病等方面有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，以及用于预防和治疗涉及疼痛、炎症等疾病或其他疾病或病况的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这类方法中有用的中间体。
• [EN] SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE<br/>[FR] SULFONAMIDOPROPIONAMIDES SUBSTITUES ET PROCEDES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2006036664A1

  公开（公告）日：2006-04-06

  This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating inflammation-related disorders, including pain.

  这项发明属于药物代理领域，具体涉及化合物、组合物、用途和治疗与炎症相关的疾病，包括疼痛的方法。
• Aryl sulfones as novel Bradykinin B1 receptor antagonists for treatment of chronic pain
  作者：Kaustav Biswas、Toshihiro Aya、Wenyuan Qian、Tanya A.N. Peterkin、Jian Jeffrey Chen、Jason Human、Randall W. Hungate、Gondi Kumar、Leyla Arik、Dianna Lester-Zeiner、Gloria Biddlecome、Barton H. Manning、Hong Sun、Hong Dong、Ming Huang、Richard Loeloff、Eileen J. Johnson、Benny C. Askew

  DOI：10.1016/j.bmcl.2008.07.108

  日期：2008.9

  We report the development of aryl sulfones as Bradykinin B1 receptor antagonists. Variation of the linker region identified diol 23 as a potent B1 antagonist, while modifications of the aryl moiety led to compound 26, both of which were efficacious in rabbit biochemical challenge and pain models.

  我们报告芳烃砜作为缓激肽B1受体拮抗剂的发展。接头区域的变化将二醇23鉴定为有效的B1拮抗剂，而对芳基部分的修饰导致了化合物26，这两种化合物在兔生化挑战和疼痛模型中均有效。
• Substituted sulfones and methods of use
  申请人：Askew C. Benny

  公开号：US20060111347A1

  公开（公告）日：2006-05-25

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和炎症介导的疾病有效。本发明涵盖新颖的化合物、类似物、前药和其药学上可接受的衍生物、制备这些化合物的药物组合物以及预防和治疗涉及疼痛、炎症等疾病和其他不适或病况的方法。本发明还涉及制备这些化合物的过程，以及在这些过程中有用的中间体。
• Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals
  申请人：Gruenenthal GmbH

  公开号：US08158628B2

  公开（公告）日：2012-04-17

  Sulfonylated tetrahydroazolopyrazine compounds corresponding to the formula I wherein R1, R2a, R2b, R3a, R3b, R4, R8, R9a, R9b, R10, R11, A, B, W1, W2 and W3 have the meanings defined herein, pharmaceutical compositions containing such compounds, a method for the preparation of such compounds, and the use of such compounds for treating or inhibiting various types of pain and/or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

  化合物公式I对应的磺酰基四氢咪唑并吡嗪化合物，其中R1、R2a、R2b、R3a、R3b、R4、R8、R9a、R9b、R10、R11、A、B、W1、W2和W3的含义在此定义，包含这种化合物的药物组合物，制备这种化合物的方法，以及利用这种化合物治疗或抑制至少部分由激肽酶1受体（B1R）介导的各种类型的疼痛和/或其他情况的用途。